Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 5:23 PM
Ignite Modification Date:
2025-12-26 @ 5:23 PM
NCT ID:
NCT06920706
Eligibility Criteria:
Inclusion Criteria:
* Patient age≥18 years;
* No gender preference;
* Diagnosed with acute ischemic stroke;
* From onset to treatment ≤48 h;
* 6≤ NIHSS scores ≤25;
* Premorbid mRS ≤1;
* Signed informed consent.
Exclusion Criteria:
* Baseline HAMD-24 scores ≥8;
* Infarction area overlapped with the area where the DTI-ALPS index is calculated;
* A history of severe mental illness such as depression, bipolar disorder, and schizophrenia;
* A history of mental disorders caused by other organic diseases, such as post-Parkinson depression;
* Participants with cognitive impairment, disturbance of consciousness, severe hearing impairment, or aphasia who were unable to cooperate with the assessment;
* A history of autoimmune diseases (such as multiple sclerosis, neuromyelitis optica spectrum disorders, systemic lupus erythematosus, etc.), malignant tumors, or obstructive sleep apnea hypopnea syndrome;
* Intracranial tumor, arteriovenous malformation, or aneurysm;
* Uncontrolled severe hypertension (systolic pressure \>180mmHg or diastolic pressure \>110 mmHg after drug treatment) ;
* Subclavian artery stenosis≥50% or subclavian steal syndrome;
* Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.;
* Severe coagulation dysfunction, platelet count \< 100×10\^9/L, cardiac dysfunction (NYHA class Ⅲ or above), hepatic dysfunction (aspartate aminotransferase and/or alanine aminotransferase \> 3 times the upper limit of normal), or renal dysfunction (serum creatinine \> 265μmol/L);
* Any contraindication for magnetic resonance imaging: metal implants, claustrophobia, etc.;
* Women known to be pregnant or lactating, or have a positive pregnancy test;
* Participating in other clinical trials within three months;
* Participants not suitable for this clinical studies considered by researcher.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06920706
Study Brief:
Protocol Section:
NCT06920706